ReviewJHEP reports : innovation in hepatology2022
What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.
Review in JHEP reports : innovation in hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 47 citations in OpenAlex.
- Socioeconomic Inequalities in Receipt of Curative-Intent Treatment and Survival After Surveillance-Detected Hepatocellular Carcinoma: A Nationwide Cohort Study.Alimentary pharmacology & therapeutics · 2026Article
- Limited association between liver stiffness and clinical outcomes in Fontan-associated liver disease: a retrospective analysis.International journal of cardiology. Congenital heart disease · 2026Article
- Stereotactic body radiotherapy and other locoregional therapies for hepatocellular carcinoma in patients with cirrhosis: real-world treatment allocation, BCLC-stratified outcomes, and prognostic determinants.Discover oncology · 2026Article
- The value of protein induced by vitamin K absence or antagonist-II (PIVKA) in predicting the efficacy of transhepatic arterial chemoembolisation (TACE): A retrospective study.Journal of medical biochemistry · 2026Article
- The global economic burden of cirrhosis and other chronic liver diseases: A health-augmented macroeconomic modeling study.Hepatology communications · 2026Article
- Disparities in access to systemic therapies for patients with hepatocellular carcinoma: an analysis from the International Liver Cancer Association.The Lancet regional health. Europe · 2025Review
- Review
- International perspectives on LI-RADS.Abdominal radiology (New York) · 2025Review
- Beyond the Cure: Navigating Hepatocellular Risk and Surveillance after Hepatitis C Eradication in the Direct-acting Antiviral Era.Journal of clinical and translational hepatology · 2025Review
- Overexpression of c-Myc triggers p62 aggregation-mediated mitochondrial mitophagy in cabozantinib resistance of hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2025Article
- Evolving epidemiology of HCC in Spain.JHEP reports : innovation in hepatology · 2025Article
- Article
- Role of hepatotropic viruses in promoting hepatocellular carcinoma-current knowledge and recent advances.Medical oncology (Northwood, London, England) · 2025Review
- Radiofrequency ablation for peribiliary hepatocellular carcinoma: propensity score matching analysis.Insights into imaging · 2025Article
- Gastrointestinal side effects in hepatocellular carcinoma patients receiving transarterial chemoembolization: a meta-analysis of 81 studies and 9495 patients.Therapeutic advances in medical oncology · 2025Article
- Study on the Mechanism of QRICH1 Mediating PRMT1 to Regulate the Arginine Methylation Modification of cGAS to Promote Arsenics-Induced Pyroptosis in Hepatocellular Carcinoma Cells.Journal of hepatocellular carcinoma · 2025Article
- Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.Journal of cachexia, sarcopenia and muscle · 2024Article
- Role of Epigenetic Factors in Determining the Biological Behavior and Prognosis of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2024Article
- New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024Article
- Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.Cell death & disease · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 9 institutions in 6 countries.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a major public health problem worldwide for which the incidence and mortality are similar, pointing to the lack of effective treatment options. Knowing the different issues involved in the management of HCC, from risk factors to screening and management, is essential to improve the prognosis and quality of life of affected individuals. This document summarises the current state of knowledge and the unmet needs for all the different stakeholders in the care of liver cancer, meaning patients, relatives, physicians, regulatory agencies and health authorities so that optimal care can be delivered to patients. The document was commissioned by the International Liver Cancer Association and was reviewed by senior members, including two ex-presidents of the Association. This document lays out the recommended approaches to the societal management of HCC based on the economic status of a given region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.